Clinical Trial Update: Arsenic Trioxide in Treating Patients With Urothelial Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating arsenic trioxide in patients with recurrent urothelial cancers (including bladder, renal pelvis, ureter, and urethral cancer…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma of the Bladder
• Urothelial Carcinoma of the Renal Pelvis
• Urothelial Carcinoma of the Ureter
• Urothelial Carcinoma of the Urethra

Drugs mentioned

• Arsenic Trioxide (arsenic trioxide)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer | Phase 2 | Status: COMPLETED